AffaMed Therapeutics
AffaMed Therapeutics is a Shanghai-based, late clinical-stage biopharma founded in 2019 by CBC Group that in-licenses and develops ophthalmology and CNS therapies for Greater China, Korea, and ASEAN, including DEXTENZA, bispecific antibodies, and a premium IOL portfolio via its SIFI joint venture.
- Company typePrivate
- Founded2019
- HeadquartersHongkou, China
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What AffaMed Therapeutics does
AffaMed Therapeutics is a late clinical-stage biopharmaceutical company headquartered in Shanghai with additional offices in Beijing, founded in 2019 by CBC Group. The company in-licenses and develops therapeutics for ophthalmology and central nervous system (CNS) disorders, targeting Greater China, South Korea, and ASEAN markets. Its clinical pipeline spans DEXTENZA (a sustained-release dexamethasone intracanalicular insert for ocular inflammation and pain, FDA-approved and in Phase 3 in China), AM712 and AG-73305 (bispecific biologics targeting VEGF/Ang-2 and VEGF/integrin for retinal disease), Risuteganib/Luminate (in-licensed from Hanmi for Dry AMD), and PH94B (a CNS candidate for social anxiety disorder acquired through the 2020 merger with EverInsight).
Through the AffaMed Technologies joint venture with SIFI, the company also develops and commercializes a premium intraocular lens (IOL) portfolio (MINI WELL, MINI WELL TORIC, MINI WELL PROXA, EVOLUX, MINI 4 Ready), with TFDA approvals secured in Taiwan and an NMPA trial ongoing in China.
The business model is asset-light regional commercialization: AffaMed acquires Greater China and pan-Asia rights to global innovations, advances them through local clinical and regulatory pathways (NMPA, HSA, TFDA), and commercializes via direct hospital sales, distribution partnerships (notably AIER Eye Hospital), the Boao LeCheng early-access channel, and the SIFI IOL joint venture. Revenue mechanics today are dominated by licensing/milestone economics and early IOL sales, with future drivers being DEXTENZA royalties, premium IOL unit sales, and biosimilar/partnered programs including Samsung Bioepis and Kissei.
AffaMed Therapeutics firmographics
Firmographics- Name
- AffaMed Therapeutics
- Legal name
- AffaMed Therapeutics
- Website
- https://affamed.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- AffaMed Therapeutics is a Shanghai-based, late clinical-stage biopharma founded in 2019 by CBC Group that in-licenses and develops ophthalmology and CNS therapies for Greater China, Korea, and ASEAN, including DEXTENZA, bispecific antibodies, and a premium IOL portfolio via its SIFI joint venture.
- Ownership category
- akta.pro rank
AffaMed Therapeutics industry classification
Industry- Product category
- Ophthalmic Biopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Ophthalmic Goods Manufacturing (339115), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Pharmaceutical Preparations (2834), Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
- akta.pro secondary industries
- Ophthalmology Pharmaceuticals (HLAIAAAL), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where AffaMed Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Hongkou
- HQ country
- China
- HQ region
- Asia
Offices2 records
Markets served
AffaMed Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: AffaMed develops and commercializes innovative pharmaceutical products in ophthalmology and CNS. Revenue will be generated from product sales following regulatory approvals in Greater China, Korea, and ASEAN markets.
- Medical Device (IOL) Sales: Through the AffaMed Technologies joint venture with SIFI, the company develops, manufactures, and commercializes premium intraocular lenses (IOLs) including MINI WELL, MINI WELL TORIC, MINI WELL PROXA, EVOLUX, and MINI 4 Ready in Greater China market.
- Licensing and Milestone Payments: As a biopharmaceutical company focused on in-licensing, the company receives upfront license fees, development milestones, regulatory milestones, sales milestones, and tiered royalties from licensing agreements with global pharmaceutical partners.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
AffaMed Therapeutics product offering
Product offeringCore offering
AffaMed Therapeutics develops and commercializes late clinical-stage pharmaceutical products, premium intraocular lenses (IOLs), and digital therapies for ophthalmology and CNS disorders. The company in-licenses innovative therapies from global partners, advances them through clinical development, and commercializes approved products in Greater China, Korea, and ASEAN markets through its own sales teams, the AffaMed Technologies joint venture with SIFI, and regional distribution partners.
Product overview
AffaMed Therapeutics is a late clinical-stage biopharmaceutical company focused on developing and commercializing transformative pharmaceutical, digital, and surgical products in ophthalmology. The company's portfolio consists of drug products including DEXTENZA (a sustained-release dexamethasone insert), bispecific biologics like AM712 for retinal diseases, and a comprehensive portfolio of premium intraocular lenses (IOLs) through its AffaMed Technologies joint venture with SIFI, including MINI WELL, MINI WELL TORIC, MINI WELL PROXA, EVOLUX, and MINI 4 Ready. The company also develops neuroscience candidates like PH94B for social anxiety disorder. AffaMed operates through in-licensing and partnership agreements with global pharmaceutical companies to bring innovative therapies to the Greater China market and beyond.
Differentiator
Problem solved
Functional benefit
Brands
- AffaMed Technologies: Joint venture with SIFI S.p.A. for developing, manufacturing, and commercializing premium intraocular lenses (IOLs) in Greater China market
- DEXTENZA
- MINI WELL
- MINI WELL TORIC
- MINI WELL PROXA
- EVOLUX
- MINI 4 Ready
Products and services
- DEXTENZA (0.4 mg dexamethasone ophthalmic insert) Corticosteroid intracanalicular insert placed in the punctum that delivers preservative-free dexamethasone for up to 30 days for the treatment of ocular inflammation and pain following ophthalmic surgery, and ocular itching associated with allergic conjunctivitis. Sold to hospitals and ophthalmic surgery centers in Greater China, Korea, and ASEAN.
- MINI WELL (Extended Depth-of-Focus IOL) First progressive Extended Depth-of-Focus (EDOF) aspheric intraocular lens for presbyopia correction, providing far, intermediate, and near vision. Based on SIFI's patented wavefront progressive technology. Sold to ophthalmic surgeons and hospitals performing cataract surgery in Greater China.
- MINI WELL TORIC (EDOF IOL with Toric correction) Toric version of MINI WELL EDOF IOL that corrects pre-existing corneal astigmatism up to 3.0D while providing progressive extended depth-of-focus vision. Sold to cataract surgery centers in Greater China via the AffaMed Technologies joint venture.
- MINI WELL PROXA (Near-vision EDOF IOL) Extended Depth-of-Focus intraocular lens designed to bridge near-vision at 30-35cm while maintaining MINI WELL's qualitative and technical characteristics. Sold to ophthalmic surgery hospitals in Greater China.
- MINI 4 Ready (Monofocal IOL) One-piece UV-filtering aspheric monofocal IOL for posterior chamber implantation to replace the human crystalline lens in correction of aphakia in adult patients undergoing cataract surgery. Sold to ophthalmic hospitals in Greater China through AffaMed Technologies.
- EVOLUX (Extended Monofocal IOL) Novel extended monofocal intraocular lens using non-diffractive wavefront engineering to provide better intermediate vision with equivalent distance vision and very low pupil dependency. Sold to cataract surgery centers through the AffaMed Technologies joint venture.
- AM712 (ASKG712) Novel bispecific biologic molecule blocking both VEGF and Ang-2 pathways for treatment of retinal vascular diseases including neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Licensed globally ex-Asia plus Japan from AskGene Pharma; intended for global pharma partners and retinal specialists.
- AM008 (OTX-TIC, travoprost intracameral implant) Travoprost intracameral implant for reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Licensed from Ocular Therapeutix for development in Greater China, Korea, and ASEAN markets; intended for glaucoma specialists and hospitals.
- AG-73305 (Bi-specific Fc-fusion Protein) First-in-class bi-specific Fc-fusion protein simultaneously binding VEGF and integrins for treatment of diabetic macular edema (DME), neovascular AMD, and retinal vein occlusion (RVO). Licensed from Allgenesis for Greater China, South Korea, and ASEAN; in development for retinal specialists and ophthalmology centers.
- Risuteganib (Luminate/AM011) First-in-class integrin regulator with a novel mechanism regulating multiple oxidative stress pathways including mitochondrial dysfunction, in development for treatment of intermediate Dry AMD. Licensed from Hanmi Pharmaceutical for Greater China; intended for retinal specialists serving the large Dry AMD patient population in China.
- PH94B (AM005) Neurosteroid Nasal Spray First-in-class, rapid-onset pherine nasal spray for acute treatment of anxiety in adults with social anxiety disorder, working through a unique mechanism binding peripheral neurons in nasal passages. Licensed from VistaGen for Greater China, South Korea, and Southeast Asia; intended for psychiatry and CNS specialty centers.
Quantifiable outcome
- DEXTENZA demonstrated significant reduction of ocular inflammation with absence of anterior chamber cells on Day 14 post-surgery in Chinese patients
- +3 more outcomes
Companies that use AffaMed Therapeutics
Customer profileNamed customers5 records
Segments2 records
Ideal customer profiles2 records
AffaMed Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
AffaMed Therapeutics partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered major, core and minor.
- AIER Eye Hospital GroupmajorStrategic cooperation with AIER Eye Hospital in Boao LeCheng Pilot Zone for Early and Pilot Implementation clinical research, real world data studies, and building international clinical research base for ophthalmology. Leverages Boao's innovation policy to introduce innovative ophthalmic products.
- Primal Chemical Co., Ltd.majorStrategic partnership with Primal Chemical to market IOLs (MINI WELL, MINI WELL TORIC, MINI WELL PROXA, MINI 4 READY) and DEXTENZA in Hong Kong and Macau. Primal Chemical distributes through network covering government & private hospitals, private clinics, pharmacies, chain stores, and trade stores.
- Hanmi PharmaceuticalcoreLicensing agreement for Risuteganib (Luminate), a first-in-class integrin regulator for treatment of intermediate Dry AMD in Greater China. Hanmi to receive up to USD145 million including upfront fee of USD6 million, and development, regulatory and sales milestone payments plus tiered royalties. Luminate received CTA approval in China in September 2023.
- Allgenesis BiotherapeuticscoreLicensing agreement for AG-73305, a first-in-class bi-specific molecule targeting VEGF and integrins for treatment of DME, nAMD, RVO, and other retinal diseases. AffaMed received exclusive rights for Greater China, South Korea, and ASEAN markets. Allgenesis eligible for upfront, development, regulatory, commercial milestones, and tiered royalties.
- Wenzhou Medical University Affiliated Eye HospitalminorStrategic cooperation agreement for clinical research collaboration, academic exchange, and professional talent training in ophthalmology. Leverages the hospital's clinical, teaching, and R&D capabilities along with Boao LeCheng innovation platform.
- SIFI S.p.A.coreJoint venture AffaMed Technologies established in April 2021 to develop, manufacture, and commercialize premium IOLs in Greater China. AffaMed provides funding, clinical development, regulatory affairs and commercial operations. SIFI contributes IP, technical and manufacturing expertise. Exclusive rights to MINI WELL, MINI WELL TORIC, MINI WELL PROXA, EVOLUX, MINI 4 Ready IOLs.
- AskGene Pharma Inc.coreLicensing agreement for exclusive rights to develop, manufacture, and commercialize AM712 (ASKG712), a novel bispecific biologic blocking VEGF and Ang-2, in ex-Asia plus Japan territories globally. AffaMed received IND clearance from US FDA in February 2022 and initiated Phase 1 study in May 2022.
- Ocular Therapeutix, Inc.coreExclusive licensing agreement for development and commercialization of DEXTENZA (0.4mg dexamethasone ophthalmic insert) in Greater China, South Korea, and ASEAN markets. DEXTENZA is approved in U.S. for treatment of ocular inflammation and pain post-surgery and ocular itching from allergic conjunctivitis. Also licensed OTX-TIC for glaucoma in same territories.
- Kissei PharmaceuticalminorExclusive licensing agreement with Kissei Pharmaceutical to develop and commercialize KDT-3594 for Parkinson's Disease in Greater China and Southeast Asia.
- VistaGen TherapeuticscoreStrategic licensing and collaboration agreement for clinical development and commercialization of PH94B (AM005) neurosteroid nasal spray for acute treatment of social anxiety disorder in China, South Korea, and Southeast Asia. PH94B is in PALISADE Global Phase 3 trial.
- Samsung BioepisminorPartnership with Samsung Bioepis to develop and commercialize biosimilars referencing ranibizumab (Lucentis) and aflibercept (Eylea) in China and Singapore.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
AffaMed Therapeutics competitors and assessment
Company assessmentDirect peers
- Zhaoke Ophthalmology: Hong Kong-listed clinical-stage ophthalmology company developing a portfolio of innovative therapies and devices for major eye diseases in Greater China and Asia. Zhaoke shares AffaMed's late-clinical-stage profile and Greater China-focused ophthalmology development model, making it a directly comparable regional peer.
- Eyebright Medical Technology: China-based ophthalmic medical device and pharmaceutical company developing intraocular lenses, surgical instruments, and ophthalmic drugs. Directly comparable to AffaMed across the IOL product line (including premium IOLs) and the broader China ophthalmology commercial footprint.
- Ocular Therapeutix: US-based biopharmaceutical company that developed DEXTENZA and OTX-TIC, both of which are licensed to AffaMed for Greater China, Korea, and ASEAN. A direct upstream peer sharing the same hydrogel intracanalicular and intracameral implant technology platform.
- SIFI S.p.A. Italian ophthalmic company and AffaMed's joint venture partner in AffaMed Technologies, providing the patented wavefront progressive EDOF IOL technology and MINI WELL product family. Comparable as a premium IOL innovator with overlapping R&D capabilities.
- Chengdu Kanghong Pharmaceutical: China-based biopharmaceutical company marketing conbercept (KH-902), a leading anti-VEGF therapy for nAMD in China. Direct competitor to AffaMed's AM712 and AG-73305 in the retinal disease space and a benchmark for commercializing ophthalmology biologics in China.
Broad incumbents
- Zai Lab: Greater China-focused biopharmaceutical company with a diversified pipeline spanning ophthalmology, oncology, and autoimmune diseases. Closely comparable business model of in-licensing global innovative therapies and commercializing them in Greater China, though across a much broader therapeutic footprint.
- Innovent Biologics: China-based biopharmaceutical company with a deep late-stage pipeline including oncology and ophthalmology assets. Comparable in scale and Chinese commercial reach, and relevant as a competitor in retinal disease biologics and a benchmark for biotech commercialization in China.
- Regeneron Pharmaceuticals: Developer of Eylea (aflibercept), the global market-leading anti-VEGF therapy for nAMD, DME, and RVO. The primary incumbent AffaMed's bispecific biologics (AM712, AG-73305) will compete against, particularly in Asia-Pacific markets.
- Alcon: Global leader in surgical ophthalmology including premium intraocular lenses (PanOptix, Vivity) and cataract surgery equipment. The principal incumbent competitor to AffaMed Technologies' premium IOL portfolio in Greater China and ASEAN markets.
Emerging players
- Hanmi Pharmaceutical: Korean pharmaceutical company that licensed Risuteganib (Luminate) to AffaMed for Greater China. Comparable as an Asia-based innovator developing novel ophthalmology and specialty pharma assets, with an overlapping research base in integrin-targeting therapies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
AffaMed Therapeutics social profiles
Digital presenceAffaMed Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
AffaMed Therapeutics leadership team
Management profileNumber of profiles
Profiles7 records
AffaMed Therapeutics subsidiaries and ownership
Company hierarchySubsidiaries1 record
AffaMed Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AffaMed Therapeutics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AffaMed Therapeutics
What does AffaMed Therapeutics do?
AffaMed Therapeutics develops and commercializes late clinical-stage pharmaceutical products, premium intraocular lenses (IOLs), and digital therapies for ophthalmology and CNS disorders. The company in-licenses innovative therapies from global partners, advances them through clinical development, and commercializes approved products in Greater China, Korea, and ASEAN markets through its own sales teams, the AffaMed Technologies joint venture with SIFI, and regional distribution partners.
Is AffaMed Therapeutics a public or private company?
AffaMed Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was AffaMed Therapeutics founded?
AffaMed Therapeutics was founded in 2019. It employs 51 to 100 people.
Where is AffaMed Therapeutics based?
AffaMed Therapeutics is headquartered in Hongkou, China, in the Asia region.
How does AffaMed Therapeutics make money?
Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are medical Device (IOL) Sales and licensing and Milestone Payments.
Who are AffaMed Therapeutics's main competitors?
Direct peers on record are Zhaoke Ophthalmology, Eyebright Medical Technology, Ocular Therapeutix, SIFI S.p.A. and Chengdu Kanghong Pharmaceutical. Broad incumbents are Zai Lab, Innovent Biologics, Regeneron Pharmaceuticals and Alcon. Hanmi Pharmaceutical is listed as an emerging player.
Does AffaMed Therapeutics have an API?
No public API is recorded for AffaMed Therapeutics.
What industry is AffaMed Therapeutics in?
AffaMed Therapeutics's product category is Ophthalmic Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals, with a secondary code of HLAIAAAL, Ophthalmology Pharmaceuticals. Its NAICS code is 32541 and its SIC code is 2834.